BLOG

F2G Announces FDA Filing Acceptance of NDA for the Treatment of Invasive Fungal Infections

Biotech company F2G announced today the FDA has accepted its NDA filing for its antifungal therapy, Olorofim. The FDA has set the Prescription Drug User Fee Act (PDUFA) date for June 17, 2023.